{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:46:09Z","timestamp":1790437569078,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,8,23]],"date-time":"2012-08-23T00:00:00Z","timestamp":1345680000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s00380-012-0274-1","type":"journal-article","created":{"date-parts":[[2012,8,22]],"date-time":"2012-08-22T06:55:41Z","timestamp":1345618541000},"page":"480-489","source":"Crossref","is-referenced-by-count":21,"title":["L\/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease"],"prefix":"10.1007","volume":"28","author":[{"given":"Masanori","family":"Abe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Inoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Soma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,23]]},"reference":[{"key":"274_CR1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ki.2010.531","volume":"80","author":"RT Gansevoort","year":"2011","unstructured":"Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, The Chronic Kidney Disease Prognosis Consortium (2011) Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 80:93\u2013104","journal-title":"Kidney Int"},{"key":"274_CR2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ki.2010.536","volume":"79","author":"M Velde van der","year":"2011","unstructured":"van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, de Jong PE, Gansevoort RT, The Chronic Kidney Disease Prognosis Consortium (2011) Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 79:1341\u20131352","journal-title":"Kidney Int"},{"key":"274_CR3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jama.2010.39","volume":"303","author":"BR Hemmelgarn","year":"2010","unstructured":"Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, Wiebe N, Tonelli M, for the Alberta Kidney Disease Network (2010) Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303:423\u2013429","journal-title":"JAMA"},{"key":"274_CR4","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1046\/j.1523-1755.2003.00033.x","volume":"63","author":"P Ruggenenti","year":"2003","unstructured":"Ruggenenti P, Perna A, Remuzzi G (2003) Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 63:2254\u20132261","journal-title":"Kidney Int"},{"key":"274_CR5","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","volume":"110","author":"D Zeeuw de","year":"2004","unstructured":"de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110:921\u2013927","journal-title":"Circulation"},{"key":"274_CR6","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456\u20131462","journal-title":"N Engl J Med"},{"key":"274_CR7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper MD, De Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861\u2013869","journal-title":"N Engl J Med"},{"key":"274_CR8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev.cellbio.16.1.521","volume":"16","author":"WA Catterall","year":"2000","unstructured":"Catterall WA (2000) Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol 16:521\u2013555","journal-title":"Annu Rev Cell Dev Biol"},{"key":"274_CR9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1161\/01.RES.0000256155.31133.49","volume":"100","author":"K Hayashi","year":"2007","unstructured":"Hayashi K, Wakino S, Sugano N, Ozawa Y, Saruta T, Homma K (2007) Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 100:342\u2013353","journal-title":"Circ Res"},{"key":"274_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000085713","volume":"101","author":"T Konda","year":"2005","unstructured":"Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T (2005) The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 101:1\u201313","journal-title":"Nephron Physiol"},{"key":"274_CR11","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/00004872-200205000-00035","volume":"20","author":"X Zhou","year":"2002","unstructured":"Zhou X, Ono H, Ono Y, Frohlich ED (2002) N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME\/SHR model. J Hypertens 20:993\u20131000","journal-title":"J Hypertens"},{"key":"274_CR12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1536\/ihj.49.723","volume":"49","author":"Y Konno","year":"2008","unstructured":"Konno Y, Kimura K (2008) Vasodilatory effect of cilnidipine, an L-type and N-type calcium channel blocker, on rat kidney glomerular arteries. Int Heart J 49:723\u2013732","journal-title":"Int Heart J"},{"key":"274_CR13","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1210\/en.137.11.4817","volume":"137","author":"MF Rossier","year":"1996","unstructured":"Rossier MF, Burnay MM, Vallotton MB, Capponi AM (1996) Distinct functions of T- and L-type calcium channels during activation of bovine adrenal glomerulosa cells. Endocrinology 137:4817\u20134826","journal-title":"Endocrinology"},{"key":"274_CR14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/01.mnh.0000165889.60254.98","volume":"14","author":"NJ Brown","year":"2005","unstructured":"Brown NJ (2005) Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 14:235\u2013241","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"274_CR15","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","volume":"70","author":"S Bianchi","year":"2006","unstructured":"Bianchi S, Bigazzi R, Campese M (2006) Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 70:2116\u20132123","journal-title":"Kidney Int"},{"key":"274_CR16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/hr.2010.191","volume":"34","author":"S Aritomi","year":"2011","unstructured":"Aritomi S, Wagatsuma H, Numata T, Uriu Y, Nogi Y, Mitsui A, Konda T, Mori Y, Yoshimura M (2011) Expression of N-type calcium channels in human adrenocortical cells and their contribution to corticosteroid synthesis. Hypertens Res 34:193\u2013201","journal-title":"Hypertens Res"},{"key":"274_CR17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.HYP.0000201443.63240.a7","volume":"47","author":"EL Shiffrin","year":"2006","unstructured":"Shiffrin EL (2006) Effects of aldosterone on the vasculature. Hypertension 47:312\u2013318","journal-title":"Hypertension"},{"key":"274_CR18","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1681\/ASN.2005040390","volume":"16","author":"K Miyata","year":"2005","unstructured":"Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, Kimura S, Yukimura T, Kiyomoto H, Kohno M, Abe Y, Nishiyama A (2005) Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 16:2906\u20132912","journal-title":"J Am Soc Nephrol"},{"key":"274_CR19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lab.2003.08.001","volume":"143","author":"A Kamijo","year":"2004","unstructured":"Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, Hirano N, Hirata Y, Goto A, Omata M (2004) Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 143:23\u201330","journal-title":"J Lab Clin Med"},{"key":"274_CR20","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.2337\/diacare.28.11.2728","volume":"28","author":"T Nakamura","year":"2005","unstructured":"Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H (2005) Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 28:2728\u20132732","journal-title":"Diabetes Care"},{"key":"274_CR21","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.5551\/jat.9084","volume":"18","author":"M Abe","year":"2011","unstructured":"Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M (2011) Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb 18:1018\u20131028","journal-title":"J Atheroscler Thromb"},{"key":"274_CR22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.lab.2004.12.003","volume":"145","author":"A Kamijo","year":"2005","unstructured":"Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Kimura K (2005) Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med 145:125\u2013133","journal-title":"J Lab Clin Med"},{"key":"274_CR23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000210396","volume":"30","author":"T Konda","year":"2009","unstructured":"Konda T, Enomoto A, Aritomi S, Niinuma K, Koganei H, Ogawa T, Nitta K (2009) Different effects of L\/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR\/Izm. Am J Nephrol 30:155\u2013161","journal-title":"Am J Nephrol"},{"key":"274_CR24","author":"S Aritomi","year":"2011","unstructured":"Aritomi S, Konda T, Yoshimura M (2011) L\/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action. Heart Vessels. doi: 10.1007\/s00380-011-0191-8","journal-title":"Heart Vessels"},{"key":"274_CR25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2010.483","volume":"80","author":"AS Levey","year":"2011","unstructured":"Levey AS, de Jong PE, Coresh J, EI Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU (2011) The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int 80:17\u201328","journal-title":"Kidney Int"},{"key":"274_CR26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/hr.2008.18","volume":"32","author":"Japanese Society of Hypertension","year":"2009","unstructured":"Japanese Society of Hypertension (2009) Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertension Res 32:4\u2013107","journal-title":"Hypertension Res"},{"key":"274_CR27","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982\u2013992","journal-title":"Am J Kidney Dis"},{"key":"274_CR28","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/sj.ki.5002623","volume":"72","author":"T Fujita","year":"2007","unstructured":"Fujita T, Ando K, Nishimura H (2007) Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic kidney disease. Kidney Int 72:1543\u20131549","journal-title":"Kidney Int"},{"key":"274_CR29","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1517\/13543784.2010.505918","volume":"19","author":"M Abe","year":"2010","unstructured":"Abe M, Okada K, Maruyama N, Matsumoto S, Maruyama T, Fujita T, Matsumoto K, Soma M (2010) Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease. Expert Opin Investig Drugs 19:1027\u20131037","journal-title":"Expert Opin Investig Drugs"},{"key":"274_CR30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/MAJ.0b013e3181c643df","volume":"339","author":"T Nakamura","year":"2010","unstructured":"Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Sugaya T, Yamagishi S, Yamada S, Koide H (2010) Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. Am J Med Sci 339:157\u2013163","journal-title":"Am J Med Sci"},{"key":"274_CR31","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/hr.2010.221","volume":"34","author":"M Abe","year":"2011","unstructured":"Abe M, Okada K, Maruyama N, Matsumoto S, Maruyama T, Fujita T, Matsumoto K, Soma M (2011) Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertes Res 34:268\u2013273","journal-title":"Hypertes Res"},{"key":"274_CR32","doi-asserted-by":"crossref","first-page":"R26","DOI":"10.1152\/ajpregu.00424.2007","volume":"294","author":"JC Ferreira","year":"2008","unstructured":"Ferreira JC, Bacurau AV, Evangelista FS, Coelho MA, Oliveira EM, Casarini DE, Krieger JE, Brum PC (2008) The role of local and systemic renin angiotensin system activation in a genetic model of sympathetic hyperactivity-induced heart failure in mice. Am J Physiol Regul Integr Comp Physiol 294:R26\u2013R32","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"274_CR33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00380-009-1171-0","volume":"25","author":"Q Zhao","year":"2010","unstructured":"Zhao Q, Wu TG, Lin Y, Li B, Luo JY, Wang LX (2010) Low-dose nesiritide improves renal function in heart failure patients following acute myocardial infarction. Heart Vessels 25:97\u2013103","journal-title":"Heart Vessels"},{"key":"274_CR34","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/j.1476-5381.2009.00407.x","volume":"158","author":"A Takahara","year":"2009","unstructured":"Takahara A, Nakamura Y, Wagatsuma H, Aritomi S, Nakayama A, Satoh Y, Akie Y, Sugiyama A (2009) Long-term blockade of L\/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart. Br J Pharmacol 158:1366\u20131374","journal-title":"Br J Pharmacol"},{"key":"274_CR35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0014-2999(01)00738-5","volume":"413","author":"T Konda","year":"2001","unstructured":"Konda T, Takahara A, Maeda K, Dohmoto H, Yoshimoto R (2001) Effects of a dual L\/N-type Ca2+ channel blocker cilnidipine on neutrally mediated chronotropic response in anesthetized dogs. Eur J Pharmacol 413:117\u2013120","journal-title":"Eur J Pharmacol"},{"key":"274_CR36","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1097\/HJH.0b013e32833d01dd","volume":"28","author":"T Konoshita","year":"2010","unstructured":"Konoshita T, Makino Y, Kimura T, Fujii M, Wakahara S, Arakawa K, Inoki I, Nakamura H, Miyamori I, The Genomic Disease Outcome Consortium (G-DOC) Study Investigators (2010) A new-generation N\/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker. J Hypertens 28:2156\u20132160","journal-title":"J Hypertens"},{"key":"274_CR37","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.ki.5000081","volume":"69","author":"R Agarwal","year":"2006","unstructured":"Agarwal R, Andersen MJ (2006) Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. Kidney Int 69:406\u2013411","journal-title":"Kidney Int"},{"key":"274_CR38","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1159\/000146028","volume":"28","author":"T Okada","year":"2008","unstructured":"Okada T, Nakao T, Matsumoto H, Nagaoka Y (2008) Value of morning home blood pressure as a predictor of decline in renal function patients with chronic kidney disease. Am J Nephrol 28:982\u2013989","journal-title":"Am J Nephrol"},{"key":"274_CR39","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/HYPERTENSIONAHA.110.165563","volume":"57","author":"A Oliveras","year":"2011","unstructured":"Oliveras A, Armario P, Martell-Claros N, Ruilope LM, de la Sierra A (2011) Urinary albumin excretion is associated with nocturnal systolic blood pressure in resistant hypertensives. Hypertension 57:556\u2013560","journal-title":"Hypertension"},{"key":"274_CR40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00125-009-1577-3","volume":"53","author":"E Ritz","year":"2010","unstructured":"Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL Jr, Katayama S, Ito S, Mimran A, Menne J, Rump LC, Januszewicz A, Haller H (2010) Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the randomized olmesartan and diabetes microalbuminuria prevention (ROADMAP) study. Diabetologia 53:49\u201357","journal-title":"Diabetologia"},{"key":"274_CR41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1755-5922.2009.00079.x","volume":"27","author":"A Takahara","year":"2009","unstructured":"Takahara A (2009) Cilnidipine: a new generation Ca2+ channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther 27:124\u2013139","journal-title":"Cardiovasc Ther"},{"key":"274_CR42","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1291\/hypres.28.1003","volume":"28","author":"S Hoshide","year":"2005","unstructured":"Hoshide S, Kario K, Ishikawa J, Eguchi K, Shimada K (2005) Comparison of the effects of cilnidipine and amlodipine on ambulatory blood pressure. Hypertens Res 28:1003\u20131008","journal-title":"Hypertens Res"},{"key":"274_CR43","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1536\/ihj.48.597","volume":"48","author":"N Ashizawa","year":"2007","unstructured":"Ashizawa N, Seto S, Shibata Y, Yano K (2007) Bedtime administration of cilnidipine controls morning hypertension. Int Heart J 48:597\u2013603","journal-title":"Int Heart J"},{"key":"274_CR44","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1291\/hypres.29.339","volume":"29","author":"T Yamagishi","year":"2006","unstructured":"Yamagishi T (2006) Beneficial effect of cilnidipine on morning hypertension and white-coat effect in patients with essential hypertension. Hypertens Res 29:339\u2013344","journal-title":"Hypertens Res"},{"key":"274_CR45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/sj.bjp.0701342","volume":"122","author":"H Uneyama","year":"1997","unstructured":"Uneyama H, Takahara A, Dohmoto H, Yoshimoto R, Inoue K, Akaike N (1997) Blockade of N-type Ca2+ current by cilnidipine (frc-8653) in acutely dissociated rat sympathetic neurons. Br J Pharmacol 122:37\u201342","journal-title":"Br J Pharmacol"},{"key":"274_CR46","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1161\/01.HYP.33.6.1447","volume":"33","author":"K Sakata","year":"1999","unstructured":"Sakata K, Shirotani M, Yoshida H, Nawada R, Obayashi K, Togi K, Miho N (1999) Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension 33:1447\u20131452","journal-title":"Hypertension"},{"key":"274_CR47","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/hr.2010.263","volume":"34","author":"JBL Faria de","year":"2011","unstructured":"de Faria JBL, Silva KC, de Faria JML (2011) The contribution of hypertension to diabetic nephropathy and retinopathy: the role of inflammation and oxidative stress. Hypertens Res 34:413\u2013422","journal-title":"Hypertens Res"},{"key":"274_CR48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/hr.2010.279","volume":"34","author":"H Toba","year":"2011","unstructured":"Toba H, Yoshida M, Tojo C, Nakano A, Oshima Y, Kojima Y, Noda K, Wang J, Kobara M, Nakata T (2011) L\/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats. Hypertens Res 34:521\u2013529","journal-title":"Hypertens Res"},{"key":"274_CR49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.semnephrol.2003.11.008","volume":"24","author":"R Agarwal","year":"2004","unstructured":"Agarwal R, Campbell RC, Warnock DG (2004) Oxidative stress in hypertension and chronic kidney disease: role of angiotensin II. Semin Nephrol 24:101\u2013114","journal-title":"Semin Nephrol"},{"key":"274_CR50","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1089\/ars.2008.2034","volume":"10","author":"R Nistala","year":"2008","unstructured":"Nistala R, Whaley-Connell A, Sowers JR (2008) Redox control of renal function and hypertension. Antioxid Redox Signal 10:2047\u20132089","journal-title":"Antioxid Redox Signal"},{"key":"274_CR51","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1523-1755.1998.00044.x","volume":"54","author":"W Kriz","year":"1998","unstructured":"Kriz W, Gretz N, Lemley KV (1998) Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 54:687\u2013697","journal-title":"Kidney Int"},{"key":"274_CR52","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","volume":"49","author":"S Shibata","year":"2007","unstructured":"Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T (2007) Podocyte as the target for aldosterone: roles of oxidative stress and Sgk 1. Hypertension 49:355\u2013364","journal-title":"Hypertension"},{"key":"274_CR53","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000316707","volume":"33","author":"T Nakamura","year":"2010","unstructured":"Nakamura T, Fujiwara N, Sato E, Ueda Y, Sugaya T, Koide H (2010) Renoprotective effects of various angiotensin II receptor blockers in patients with early-stage diabetic nephropathy. Kidney Blood Press Res 33:213\u2013220","journal-title":"Kidney Blood Press Res"},{"key":"274_CR54","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1177\/147323001003800222","volume":"38","author":"M Tanaka","year":"2010","unstructured":"Tanaka M (2010) The L\/N-type calcium channel blocker, cilnidipine, reduces heart rate and albuminuria in patients with type 2 diabetes. J Int Med Res 38:602\u2013610","journal-title":"J Int Med Res"},{"key":"274_CR55","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/10641961003667914","volume":"32","author":"Y Miwa","year":"2010","unstructured":"Miwa Y, Tsuchihashi T, Ohta Y, Tominaga M, Kawano Y, Sasaguri T, Ueno M, Matsuoka H (2010) Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors\u2014a multicenter, open, randomized trial using 24-hour urine collection. Clin Exp Hypertens 32:400\u2013405","journal-title":"Clin Exp Hypertens"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-012-0274-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00380-012-0274-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-012-0274-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:09:09Z","timestamp":1559056149000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00380-012-0274-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,23]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["274"],"URL":"https:\/\/doi.org\/10.1007\/s00380-012-0274-1","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,23]]}}}